Here's Why The Best Is Yet to Come for Novavax
Novavax (NASDAQ: NVAX) shares soared a whopping 2,700% last year. That might make you say the best times are behind this high-flying biotech stock. But I don't think the Novavax story is over. In fact, we're reaching the most interesting part of this exciting story right now -- and that means we shouldn't close the book and put it back on the shelf.
Of course, it's hard to imagine that Novavax shares will replicate their 2020 performance in 2021. But most investors would be satisfied with a steady gain over time based on sales and profit growth. And that just might be on the horizon for Novavax. Let's take a closer look at why the best is yet to come for this clinical stage biotech company.
Image source: Getty Images.
Source Fool.com
